A modeling tool for the personalization of pharmacokinetic predictions
Authors:
- Roberto Andrea AbbiatiRARoberto Andrea Abbiati
- Davide MancaDMDavide Manca
- 1 August 2016
- journal article
- Published by Elsevier in Computers & Chemical Engineering
- Vol. 91, 28-37
Abstract
No abstract availableKeywords
Funding Information
- Ministero dell’Istruzione, dell’Università e della Ricerca (20109PLMH2)
This publication has 19 references indexed in Scilit:
- Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?Biopharmaceutics & Drug Disposition, 2012
- Pharmacokinetic Considerations for Digoxin in Older PeopleThe Open Cardiovascular Medicine Journal, 2011
- Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment †British Journal of Anaesthesia, 2004
- End-stage renal failure reduces central clearance and prolongs the elimination half life of remifentanilCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2002
- Is There a Role for Therapeutic Drug Monitoring of New Anticonvulsants?Clinical Pharmacokinetics, 2000
- Best practice in therapeutic drug monitoringBritish Journal of Clinical Pharmacology, 1998
- Remifentanil and tramadolBritish Journal of Anaesthesia, 1998
- Pharmacokinetics of Remifentanil (GI87084B) and Its Major Metabolite (GI90291) in Patients Undergoing Elective Inpatient SurgeryAnesthesiology, 1993
- The Pharmacokinetics of the New Short-acting Opioid Remifentanil (GI87084B) in Healthy Adult Male VolunteersAnesthesiology, 1993
- Pharmacokinetic Drug Interactions with Phenytoin (Part I)1Clinical Pharmacokinetics, 1990